PTEN and neoplasm: These aberrations include dysregulation of oncogenes (more specifically, MYC and ERG) and tumor suppressors (including TP53, RB1, and PTEN), highlighting the disrupted balance between pro‐oncogenic and tumor‐suppressive signaling pathways.